Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neogen Corporation's sizeable $11 billion food-and-animal safety TAM still has secular tailwinds with regulation, traceability, and disease-prevention trends. Management believes this market has an overall projected 6%–7% CAGR through 2030. In that context, NEOG's Petrifilm anchors future recurring consumables and end-to-end testing ecosystem.
Neogen Corporation (NEOG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
NEOG's Q2 EPS and revenues top estimates, sending shares up 31.6% as the company raises its fiscal 2026 revenue and EBITDA outlook.
Although the revenue and EPS for Neogen (NEOG) give a sense of how its business performed in the quarter ended November 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neogen Corporation (NEOG) Q2 2026 Earnings Call Transcript
Neogen leans on new product launches and 3M Food Safety integration to offset solvency strains and macro pressures.
The consensus price target hints at a 29.9% upside potential for Neogen (NEOG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
NEOG's Q1 earnings decline 42.9% year over year, while revenues of $209.2 million top the consensus mark.
While the top- and bottom-line numbers for Neogen (NEOG) give a sense of how the business performed in the quarter ended August 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Neogen Corporation (NASDAQ:NEOG ) Q1 2026 Earnings Call October 9, 2025 8:00 AM EDT Company Participants Bill Waelke - Head of Investor Relations Mikhael Nassif - CEO, President & Director Dave Naemura Conference Call Participants Brandon Vazquez - William Blair & Company L.L.C., Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Bob Labick - CJS Securities, Inc. David Westenberg - Piper Sandler & Co., Research Division Tom DeBourcy - Nephron Research LLC Presentation Operator Good morning, ladies and gentlemen, and welcome to Neogen Corporation First Quarter FY 2026 Earnings Conference Call.
Neogen (NEOG) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.07 per share a year ago.